5 Ways to Participate in the Psychedelics Boom
March 27th, 2020
App, Exclusive, News, Policy, Top News
The psychedelics industry is quickly becoming the next frontier market for investors as the cannabis industry matures. Through a combination of cutting-edge research and decriminalization, investors are hoping that the industry moves in the same direction as medical cannabis over the coming years.
Let’s take a look at five public companies in the space and how they plan on capitalizing on these trends.
Ehave Inc. (OTC: EHVVF) is developing software-based solutions for the digital management, assessment and remediation of mental health disorders. In February, the company formed a subsidiary to focus on psychedelics and moved to acquire PsychedeliTech — a producer of the Psych conference worldwide where scientists, business leaders and investors meet to collaborate on the advancement of psychedelics.
Mind Medicine Inc. (NEO: MMED) became the first publicly-traded psychedelics pharmaceutical pure-play earlier this year. With an experienced management team, the company’s near-term goal is to develop a non-hallucinogenic version of the psychedelic ibogaine, which could help curb addiction. The company also plans to conduct a Phase 2 LSD microdosing clinical trial for adult ADHD later the year.
Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) is developing artisanal medicinal mushroom-infused products. In March, the company acquired intellectual property relating to the delivery of ketamine, anesthetics and adaptogenics. The company plans to integrate its existing medicinal mushroom extracts into these proprietary delivery systems over the coming quarters. Roadman Investments Corp. (TSXV: LITT) is also an early investor.
Revive Therapeutics Ltd. (CSE: RVV) is a cannabinoid-focused company that entered the psychedelics space in February with a letter of intent to acquire Psilocin Pharma Corp., which is developing production solutions for psilocybin. The company plans to initially sell products in countries like Brazil where psilocybin formulations are legally approved. The goal is to eventually create FDA-approved products across many conditions.
Wuhan General Group Inc. (OTC: WUHN) is actively exploring opportunities in the psychedelic medicine space. Its M2BIO division aims to create new therapies for patients suffering from mental illnesses, including psilocybin-based therapies. It also acquired a 49% stake in Biodelta Neutraceutcials.
CFN Media Contact:
Frank Lane President
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.